Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Revance Therapeutics Stock Quote

Revance Therapeutics (NASDAQ: RVNC)

$3.97
(-3.9%)
-$0.16
Price as of April 15, 2024, 4:00 p.m. ET

Revance Therapeutics Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
RVNC -86.95% -69.99% -21.40% -85%
S&P +23.57% +76.22% +11.98% +185%

Revance Therapeutics Company Info

Revance Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications. The firm focuses on production of daxibotulinumtoxinA, a botulinum toxin, for aesthetic and therapeutic indications including facial wrinkles and muscle movement disorders. The company was founded by Jacob M. Waugh and L. Daniel Browne on August 10, 1999 and is headquartered in Nashville, TN.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.